礼来公布“头对头”详细数据 替尔泊肽减重效果超过司美格鲁肽

Core Insights - Eli Lilly's tirzepatide has outperformed semaglutide in weight loss effectiveness based on the detailed results of the SURMOUNT-5 head-to-head clinical trial [2][3] Group 1: Study Overview - The SURMOUNT-5 trial is a multicenter, randomized, open-label Phase 3b study aimed at evaluating the efficacy and safety of tirzepatide compared to semaglutide in overweight adults with at least one comorbidity [2] - The trial included approximately 751 participants from the U.S. and Puerto Rico, randomized in a 1:1 ratio to receive either tirzepatide or semaglutide [3] Group 2: Weight Loss Results - At week 72, tirzepatide achieved an average weight reduction of 20.2%, while semaglutide achieved 13.7% [3] - Participants in the tirzepatide group lost an average of 22.8 kg, compared to 15.0 kg in the semaglutide group [3] - The proportion of participants achieving a weight loss of at least 15% was 64.6% for tirzepatide versus 40.1% for semaglutide [3] - Average waist circumference reduction was 18.4 cm for tirzepatide and 13.0 cm for semaglutide [3] Group 3: Safety Profile - The most common adverse events reported during the trial were mild to moderate gastrointestinal issues [4] - The discontinuation rate due to adverse events was 6.1% for the tirzepatide group and 8.0% for the semaglutide group [5]